✉news BusinessStartups first seen 6 h ago, last 12 min ago, peak #5
Immunotherapy startup Adecto shuts down, blaming risk-averse funding
Original: Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
Immunotherapy startup Adecto has closed down, with the company pointing to a 'risk-adverse funding environment' as the reason for its collapse. The closure underscores growing pressure on early-stage biotech firms as investors pull back from risky drug development bets, raising concerns about how many promising treatments may stall for lack of capital.
Why now: Biotech funding has tightened, and the startup's public blame of investors highlights wider worries about the sector's ability to raise money.
Rank over time, top of the chart is #1. 10 snapshots from 6 h ago to 12 min ago.
Evidence
- Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down · Fierce Biotech
API: https://socialmediatrends-api.osmike.com/v1/trends/720347